open access

Vol 79, No 6 (2011)
ORIGINAL PAPERS
Published online: 2011-10-25
Submitted: 2013-02-22
Get Citation

The impact of comorbidities on the length of hospital treatment in patients with chronic obstructive pulmonary disease

Adam Nowiński, Dariusz Kamiński, Damian Korzybski, Anna Stokłosa, Dorota Górecka
Pneumonol Alergol Pol 2011;79(6):388-396.

open access

Vol 79, No 6 (2011)
ORIGINAL PAPERS
Published online: 2011-10-25
Submitted: 2013-02-22

Abstract

Introduction: The aim of this study was to assess relationships of chronic obstructive pulmonary disease (COPD) comorbidities number, with the duration of hospital stay due to acute AE COPD in longitudinal prospective study.
Material and methods: We evaluated the number of re-hospitalizations, length of stay and number of comorbidities in 464 consecutive COPD patients admitted to the tertiary respiratory hospital due to AE COPD enrolled in longitudinal prospective study from 2005 to 2009 year.
Results: GOLD II stage COPD patients had 4.1 ± 1.2 comorbidities (p = 0.002), stage III 3.4 ± 1.3 and stage IV had 3.6 ± 1.2 comorbidities. Duration of hospital stay (medians) was longer in more severe patients. Duration of hospitalization correlated with urea level (r = 0.19 p < 0.001), pCO2 (r = 0.193, p = 0.0003), HCO3 (r = 0.25, p < 0.0001), haemoglobin (r = –0.18, p < 0.001), and hematocrit (r = –0.13, p = 0.008). The patients with the risk of readmission had more severe GOLD stage and were hypercapnic (pCO2 = 47.6 mmHg v. 43.9 mmHg in those without hospitalization).
Conclusions: The haemoglobin level, hypercapnia and renal function are predictors of prolonged hospitalization. Patients with more severe airflow limitation and higher pCO2 have increased risk for readmission to the hospital. More severe disease stage, clinical diagnosis of cor pulmonale or bronchiectasis was related to longer hospital stay.
Pneumonol. Alergol. Pol. 2011; 79, 6: 388–396

Abstract

Introduction: The aim of this study was to assess relationships of chronic obstructive pulmonary disease (COPD) comorbidities number, with the duration of hospital stay due to acute AE COPD in longitudinal prospective study.
Material and methods: We evaluated the number of re-hospitalizations, length of stay and number of comorbidities in 464 consecutive COPD patients admitted to the tertiary respiratory hospital due to AE COPD enrolled in longitudinal prospective study from 2005 to 2009 year.
Results: GOLD II stage COPD patients had 4.1 ± 1.2 comorbidities (p = 0.002), stage III 3.4 ± 1.3 and stage IV had 3.6 ± 1.2 comorbidities. Duration of hospital stay (medians) was longer in more severe patients. Duration of hospitalization correlated with urea level (r = 0.19 p < 0.001), pCO2 (r = 0.193, p = 0.0003), HCO3 (r = 0.25, p < 0.0001), haemoglobin (r = –0.18, p < 0.001), and hematocrit (r = –0.13, p = 0.008). The patients with the risk of readmission had more severe GOLD stage and were hypercapnic (pCO2 = 47.6 mmHg v. 43.9 mmHg in those without hospitalization).
Conclusions: The haemoglobin level, hypercapnia and renal function are predictors of prolonged hospitalization. Patients with more severe airflow limitation and higher pCO2 have increased risk for readmission to the hospital. More severe disease stage, clinical diagnosis of cor pulmonale or bronchiectasis was related to longer hospital stay.
Pneumonol. Alergol. Pol. 2011; 79, 6: 388–396
Get Citation

Keywords

COPD; comorbidities; COPD exacerbation; hospital treatment length

About this article
Title

The impact of comorbidities on the length of hospital treatment in patients with chronic obstructive pulmonary disease

Journal

Advances in Respiratory Medicine

Issue

Vol 79, No 6 (2011)

Pages

388-396

Published online

2011-10-25

Bibliographic record

Pneumonol Alergol Pol 2011;79(6):388-396.

Keywords

COPD
comorbidities
COPD exacerbation
hospital treatment length

Authors

Adam Nowiński
Dariusz Kamiński
Damian Korzybski
Anna Stokłosa
Dorota Górecka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl